Surrozen Logo FINAL Large-1.png
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
04 nov. 2024 08h30 HE | Surrozen, Inc.
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary FIbrosis
Surrozen Logo FINAL Large-1.png
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
24 sept. 2024 08h30 HE | Surrozen, Inc.
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
Surrozen Logo FINAL Large-1.png
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
12 août 2024 16h05 HE | Surrozen, Inc.
Surrozen Provides Second Quarter 2024 Financial Results and Business Update
Surrozen Logo FINAL Large-1.png
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
12 juin 2024 08h30 HE | Surrozen, Inc.
Surrozen Publishes Study in eLife Demonstrating the Promise of the SWEETS Platform, a Unique TPD Technology, to Further Enhance Wnt Signaling
Surrozen Logo FINAL Large-1.png
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
10 juin 2024 08h30 HE | Surrozen, Inc.
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen Logo FINAL Large-1.png
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
04 juin 2024 08h30 HE | Surrozen, Inc.
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
Surrozen Logo FINAL Large-1.png
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
09 mai 2024 08h30 HE | Surrozen, Inc.
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
Surrozen Logo FINAL Large-1.png
Surrozen Provides First Quarter 2024 Financial Results and Business Update
08 mai 2024 16h05 HE | Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Surrozen Logo FINAL Large-1.png
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
03 avr. 2024 08h40 HE | Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Logo FINAL Large-1.png
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 avr. 2024 08h30 HE | Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043